INVA Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of 22.15% compared to Innoviva's net margin of --. Innoviva's return on equity of 3.44% beat Perspective Therapeutics's return on equity of --.

Innoviva has a consensus price target of $19.00, signalling upside risk potential of 5.03%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.39 which suggests that it could grow by 677.99%. Given that Perspective Therapeutics has higher upside potential than Innoviva, analysts believe Perspective Therapeutics is more attractive than Innoviva.

Innoviva has a beta of 0.484, which suggesting that the stock is 51.553% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.866%.

Innoviva has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innoviva pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Innoviva quarterly revenues are $91.8M, which are larger than Perspective Therapeutics quarterly revenues of --. Innoviva's net income of $20.3M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, Innoviva's price-to-earnings ratio is 95.21x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innoviva is 4.01x versus 11.98x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Disc Medicine has a net margin of 22.15% compared to Innoviva's net margin of --. Innoviva's return on equity of 3.44% beat Disc Medicine's return on equity of --.

Innoviva has a consensus price target of $19.00, signalling upside risk potential of 5.03%. On the other hand Disc Medicine has an analysts' consensus of $98.40 which suggests that it could grow by 140%. Given that Disc Medicine has higher upside potential than Innoviva, analysts believe Disc Medicine is more attractive than Innoviva.

Innoviva has a beta of 0.484, which suggesting that the stock is 51.553% less volatile than S&P 500. In comparison Disc Medicine has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Innoviva has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Disc Medicine offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innoviva pays -- of its earnings as a dividend. Disc Medicine pays out -- of its earnings as a dividend.

Innoviva quarterly revenues are $91.8M, which are larger than Disc Medicine quarterly revenues of --. Innoviva's net income of $20.3M is higher than Disc Medicine's net income of -$29.5M. Notably, Innoviva's price-to-earnings ratio is 95.21x while Disc Medicine's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innoviva is 4.01x versus -- for Disc Medicine. Usually stocks with elevated PS ratios are considered overvalued.

Janux Therapeutics has a net margin of 22.15% compared to Innoviva's net margin of -6391.57%. Innoviva's return on equity of 3.44% beat Janux Therapeutics's return on equity of -11.37%.

Innoviva has a consensus price target of $19.00, signalling upside risk potential of 5.03%. On the other hand Janux Therapeutics has an analysts' consensus of $85.33 which suggests that it could grow by 197.43%. Given that Janux Therapeutics has higher upside potential than Innoviva, analysts believe Janux Therapeutics is more attractive than Innoviva.

Innoviva has a beta of 0.484, which suggesting that the stock is 51.553% less volatile than S&P 500. In comparison Janux Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Innoviva has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Janux Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innoviva pays -- of its earnings as a dividend. Janux Therapeutics pays out -- of its earnings as a dividend.

Innoviva quarterly revenues are $91.8M, which are larger than Janux Therapeutics quarterly revenues of $439K. Innoviva's net income of $20.3M is higher than Janux Therapeutics's net income of -$20.2M. Notably, Innoviva's price-to-earnings ratio is 95.21x while Janux Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innoviva is 4.01x versus 118.17x for Janux Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of 22.15% compared to Innoviva's net margin of -49.65%. Innoviva's return on equity of 3.44% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Innoviva has a consensus price target of $19.00, signalling upside risk potential of 5.03%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 44.56%. Given that NovaBay Pharmaceuticals has higher upside potential than Innoviva, analysts believe NovaBay Pharmaceuticals is more attractive than Innoviva.

Innoviva has a beta of 0.484, which suggesting that the stock is 51.553% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Innoviva has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innoviva pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Innoviva quarterly revenues are $91.8M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Innoviva's net income of $20.3M is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Innoviva's price-to-earnings ratio is 95.21x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innoviva is 4.01x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.